Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Vesole

Showing results (41-50 of 148) with videos related to

Pageof 15
Sort By:
British Journal of Haematology|June 17, 2021
Immune tolerance with combined allogeneic haplo-identical haematopoietic stem cell transplant and renal transplantKimberley Doucette, Neil J Shah, Michele L Donato, et al.
Blood|February 21, 2004
Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemiaMichael D Rosenblum, James L LaBelle, Chung-Che Chang, et al.
Cancer|October 20, 2004
Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group StudyIrene M Ghobrial, Rafael Fonseca, Philip R Greipp, et al.
European Journal of Haematology|December 5, 2024
Venetoclax in the Treatment of Multiple Myeloma: A Retrospective Analysis of 79 PatientsEli Zolotov, Vanisha Patel, Yedidyah Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphomaSteven M Devine, Neal Flomenberg, David H Vesole, et al.
Blood|January 25, 2002
Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor graftsWilliam R Drobyski, John Klein, Neal Flomenberg, et al.
British Journal of Haematology|November 19, 2016
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimensLarysa Sanchez, David H Vesole, Joshua R Richter, et al.
Clinical Lymphoma & Myeloma|January 19, 2007
Bortezomib-induced tumor lysis syndrome in multiple myelomaOrhan Sezer, David H Vesole, Seema Singhal, et al.
Current Stem Cell Research & Therapy|April 8, 2024
Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell BoostAyrton Bangolo, Samir Oza, Ronit Reich-Slotky, et al.
The American Journal of Surgical Pathology|April 17, 2004
Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphomaChung-Che Chang, Sara McClintock, Ronald P Cleveland, et al.
Pageof 15

Showing results (41-50 of 148) with videos related to

Sort By:
Pageof 15
British Journal of Haematology|June 17, 2021
Immune tolerance with combined allogeneic haplo-identical haematopoietic stem cell transplant and renal transplantKimberley Doucette, Neil J Shah, Michele L Donato, et al.
Blood|February 21, 2004
Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemiaMichael D Rosenblum, James L LaBelle, Chung-Che Chang, et al.
Cancer|October 20, 2004
Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group StudyIrene M Ghobrial, Rafael Fonseca, Philip R Greipp, et al.
European Journal of Haematology|December 5, 2024
Venetoclax in the Treatment of Multiple Myeloma: A Retrospective Analysis of 79 PatientsEli Zolotov, Vanisha Patel, Yedidyah Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphomaSteven M Devine, Neal Flomenberg, David H Vesole, et al.
Blood|January 25, 2002
Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor graftsWilliam R Drobyski, John Klein, Neal Flomenberg, et al.
British Journal of Haematology|November 19, 2016
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimensLarysa Sanchez, David H Vesole, Joshua R Richter, et al.
Clinical Lymphoma & Myeloma|January 19, 2007
Bortezomib-induced tumor lysis syndrome in multiple myelomaOrhan Sezer, David H Vesole, Seema Singhal, et al.
Current Stem Cell Research & Therapy|April 8, 2024
Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell BoostAyrton Bangolo, Samir Oza, Ronit Reich-Slotky, et al.
The American Journal of Surgical Pathology|April 17, 2004
Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphomaChung-Che Chang, Sara McClintock, Ronald P Cleveland, et al.
Pageof 15